A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Key facts

Study ID

NCT03369223

Run by

Bristol-Myers Squibb

People needed

356

Starts

2017-12-06

Expected to finish

2024-11-07

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
• Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists
• Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants
• Willing and able to comply with all study procedures

You may not qualify if…

• Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded
• Other active malignancy requiring concurrent intervention
• Prior organ allograft
• Active, known, or suspected autoimmune disease
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0005 — Aurora, Colorado, United States
• Local Institution - 0006 — Denver, Colorado, United States
• Local Institution - 0017 — Miami, Florida, United States
• Local Institution - 0024 — Baltimore, Maryland, United States
• Local Institution - 0001 — Hackensack, New Jersey, United States
• Local Institution - 0002 — New York, New York, United States
• Local Institution - 0003 — New York, New York, United States
• Local Institution - 0029 — Cincinnati, Ohio, United States
• Local Institution - 0013 — Eugene, Oregon, United States
• Local Institution - 0004 — Philadelphia, Pennsylvania, United States
• Local Institution - 0008 — Greenville, South Carolina, United States
• Local Institution - 0010 — Austin, Texas, United States
• Local Institution - 0009 — Dallas, Texas, United States
• Local Institution - 0021 — Houston, Texas, United States
• Local Institution - 0016 — San Antonio, Texas, United States
• Local Institution - 0011 — Tyler, Texas, United States
• Local Institution - 0012 — Leesburg, Virginia, United States
• Local Institution - 0007 — Norfolk, Virginia, United States
• Local Institution - 0018 — Vancouver, Washington, United States
• Local Institution - 0038 — Buenos Aires, Distrito Federal, Argentina
• Local Institution - 0052 — CABA, Distrito Federal, Argentina
• Local Institution - 0037 — Buenos Aires, Argentina
• Local Institution - 0015 — North Sydney, New South Wales, Australia
• Local Institution - 0014 — Adelaide, South Australia, Australia
• Local Institution - 0025 — Frankston, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.